Follow-up program for lung cancer patients treated with radiation
Standard Follow-up Program (SFP) for Lung Cancer Patients Treated With Radiotherapy or Chemoradiation
This study is trying to create a follow-up program for lung cancer patients who had radiation treatment to see how well they are doing and to gather information that could help improve future treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Medical Center Groningen Academic / other |
| Locations | 1 site (Groningen, Provincie Groningen) |
| Trial ID | NCT02421718 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a comprehensive follow-up program for lung cancer patients who have undergone radiotherapy or chemoradiation. It focuses on collecting relevant data regarding patient outcomes, treatment results, side effects, and quality of life. The goal is to create a database that links treatment data with dose-volume data from radiotherapy, which will help in developing prediction models for tumor control and toxicity. These models could eventually assist in selecting patients for proton therapy.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) with limited disease, thymoma, or lung metastases who are receiving a radiotherapy dose greater than 40 Gy.
Not a fit: Patients who do not meet the inclusion criteria or those who are not receiving the specified radiotherapy treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could enhance treatment personalization and improve outcomes for lung cancer patients.
How similar studies have performed: Other studies have shown success in developing prediction models for treatment outcomes in cancer patients, indicating that this approach has potential.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with NSCLC or SCLC-LD or thymoma or lung metastases (treated with stereotactic radiotherapy) * Patients receiving radiotherapy dose \> 40 Gy Exclusion Criteria: * Failure to comply with any of the inclusion criteria
Where this trial is running
Groningen, Provincie Groningen
- University Medical Center Groningen — Groningen, Provincie Groningen, Netherlands (Recruiting)
Study contacts
- Principal investigator: Robin Wijsman, MD — University Medical Center Groningen
- Study coordinator: Robin Wijsman, MD PhD
- Email: r.wijsman@umcg.nl
- Phone: +31503615532
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.